Search

Author/Creator Laille, Eric

1. A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment. Issue 5 (8th November 2013)

Authors:
Laille, Eric; Goel, Sanjay; Mita, Alain C.; Gabrail, Nashat Y.; Kelly, Kevin; Liu, Liangang; Songer, Stephen; Beach, Charles L.
Journal:
Pharmacotherapy
Issue:
Volume 34:Issue 5(2014)
Page Start:
440
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single‐arm, open‐label phase 2 study. Issue 3 (28th December 2017)

Authors:
Du, Xin; Lai, Yue‐Yun; Xiao, Zhijian; Liu, Ting; Hu, Yu; Sun, Aining; Li, Xiao; Shen, Zhi‐Xiang; Jin, Jie; Yu, Li; Laille, Eric; Dong, Qian; Songer, Stephen; Beach, C.L.
Journal:
Asia-Pacific journal of clinical oncology
Issue:
Volume 14:Issue 3(2018)
Page Start:
270
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher‐risk myelodysplastic syndromes. Issue 5 (25th January 2017)

Authors:
Chou, Wen‐Chien; Yeh, Su‐Peng; Hsiao, Liang‐Tsai; Lin, Sheng‐Fung; Chen, Yeu‐Chin; Chen, Tsai‐Yun; Laille, Eric; Galettis, Anoula; Dong, Qian; Songer, Steve; Beach, CL
Journal:
Asia-Pacific journal of clinical oncology
Issue:
Volume 13:Issue 5(2017)
Page Start:
e430
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies. Issue 10 (3rd September 2018)

Authors:
Savona, Michael R.; Kolibaba, Kathryn; Conkling, Paul; Kingsley, Edwin C.; Becerra, Carlos; Morris, John C.; Rifkin, Robert M.; Laille, Eric; Kellerman, Amy; Ukrainskyj, Stacey M.; Dong, Qian; Skikne, Barry S.
Journal:
American journal of hematology
Issue:
Volume 93:Issue 10(2018:Oct.)
Page Start:
1199
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. (18th January 2014)

Authors:
Laille, Eric; Savona, Michael R.; Scott, Bart L.; Boyd, Thomas E.; Dong, Qian; Skikne, Barry
Journal:
Journal of clinical pharmacology
Issue:
Volume 54:Number 6(2014:Jun.)
Page Start:
630
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Issue 13 (1st May 2021)

Authors:
Garcia-Manero, Guillermo; Santini, Valeria; Almeida, Antonio; Platzbecker, Uwe; Jonasova, Anna; Silverman, Lewis R.; Falantes, Jose; Reda, Gianluigi; Buccisano, Francesco; Fenaux, Pierre; Buckstein, Rena; Diez Campelo, Maria; Larsen, Stephen; Valcarcel, David; Vyas, Paresh; Giai, Valentina; Olíva...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 13(2021)
Page Start:
1426
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗